CAMBRIDGE, Mass., Could 24, 2023 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical firm centered on creating exactly focused therapies for clinically confirmed kinase targets in most cancers, at the moment introduced that James Porter, Ph.D., Chief Govt Officer, and Alexandra Balcom, Chief Monetary Officer, will take part in a fireplace chat through the TD Cowen 4th Annual Oncology Innovation Summit on Wednesday, Could 31, 2023, at 10:30 a.m. ET.
A reside webcast shall be out there within the Buyers part of the corporate’s web site at www.nuvalent.com, and archived for 30 days following the presentation.
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical firm centered on creating exactly focused therapies for sufferers with most cancers, designed to beat the restrictions of present therapies for clinically confirmed kinase targets. Leveraging deep experience in chemistry and structure-based drug design, we develop revolutionary small molecules which have the potential to beat resistance, reduce hostile occasions, tackle mind metastases, and drive extra sturdy responses. Nuvalent is advancing a sturdy pipeline with parallel lead applications in ROS1-positive and ALK-positive non-small cell lung most cancers (NSCLC), a program in HER2 Exon 20 insertion-positive cancers, and a number of discovery-stage analysis applications. We routinely put up info that could be necessary to traders on our web site at www.nuvalent.com. Comply with us on Twitter (@nuvalent) and LinkedIn.
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-td-cowen-4th-annual-oncology-innovation-summit-301832913.html
SOURCE Nuvalent, Inc.
Firm Codes: NASDAQ-NMS:NUVL